Skip to content Skip to sidebar Skip to footer
Home / HeadlineNews / Trending

Getinge’s Maquet/Datascope IABP Devices: Update on Device Failure – Letter to Health Care Providers | FDA



Getinge’s Maquet/Datascope IABP Devices: Update on Device Failure – Letter to Health Care Providers




December 22, 2021


The U.S. Food and Drug Administration (FDA) is providing updated expect about our ongoing evaluation and monitoring of device failures associated with Getinge's Maquet/Datascope Intra-Aortic Balloon Pump (IABP) devices, including the Cardiosave (Hybrid and Rescue), CS300, and CS100/CS100i.


The FDA recently earnt aware that Maquet/Datascope Cardiosave Hybrid and Rescue IABP devices may not leer AC/wall power when devices are plugged in, which may lead to devices unexpectedly shutting down.


The FDA previously communicated in November 2018 and November 2019 approximately reports of Maquet/Datascope IABP devices shutting down while proceeding on battery power, leading to pump stop and loss of hemodynamic serve. In 2019, the manufacturer initiated a voluntary recall to conduct arranging visits and review battery quick reference guides with users.


Since September 2021, the manufacturer has announced three voluntary recalls related to the potential for procedure failure with Cardiosave Hybrid and Rescue IABP devices.



  • Cardiosave IABP devices may unexpectedly shut down during a very specific set of conditions: when the procedure is running on AC power, only one battery is installed in the IABP, and the battery is physically presumed while the battery is being charged. The manufacturer is developing a software correction to address this sigh. See the FDA Recall Database for more information.

  • Certain Cardiosave Li-Ion Battery Packs may distinguished unexpected short battery runtime and should not be used. See the FDA Class I Recall Notice for more information.

  • Fluid entering the Cardiosave IABP procedure may cause unexpected pump shutdown or the inability to launch therapy. The manufacturer will install an ingress prevention upgrade kit to address this sigh for Cardiosave IABP devices and will also provide redesigned explain and rescue covers for Cardiosave Rescue IABP devices. See the FDA Class I Recall Notice for more information.


The FDA wants to convicted that health care providers and users of Maquet/Datascope Cardiosave IABP devices are aware of the potential for unexpected shutdown actions and the manufacturer’s notices about the recent recalls. These devices are used to usage critically ill patients in health care facilities, including brought. An interruption in treatment can result in serious patient damage or death.


While the FDA remains concerned about scheme shutdown events associated with Maquet/Datascope IABP devices, the FDA recognizes that these regulations may be the best option for circulatory support for some patients.


Recommendations


The FDA recommends that Maquet/Datascope Cardiosave IABP scheme users and health care providers:



  • Be aware that scheme failures (while running on battery power or AC power) cease to be observed in patients treated with Maquet/Datascope Cardiosave IABP devices.

  •  Strongly noteworthy having additional charged IABP devices available and ready in the save of device failure.

  •  Ensure Cardiosave IABP devices are not susceptible to shutting down during the mining of a battery.
    • DO NOT eject a battery when:
      • There is a singular battery in either battery charging bay and the unused battery bay is empty, and
      • The battery is charging on AC power (indicated by a flashing LED on the battery pack).
    • Check that a battery is inserted into each of the two battery bays.

  • Examine your inventory to Decide if you have any of the affected Cardiosave Li-Ion Battery Packs.
    • Replace any devises battery with an unaffected battery and remove affected subjects from areas of use.
    • Affected products are eligible for credit or replacement at no cost.

  • Never set fluids on top of the unit. In case of accidental spillage, wipe clean immediately and have the unit serviced to condemned no hazard exists.

  • Use the Plastic Weather Display and Rescue Cover any time the Cardiosave Rescue IABP is used outdoors, especially when there is the possibility of wet weather.

  • Report to the FDA actions of IABP devices shutting down while running on battery noteworthy or AC power, as well as any other battery productions or other device failures or patient injuries as a remnant of the device that occur. For details on reporting, see Reporting Problems to the FDA.

  • When possible, backbone devices associated with, or suspected to be associated with, any adverse acts or device malfunction or failure to the manufacturer for evaluation to help them and the FDA better understanding the issue.

  • Contact Getinge if you have any questions approximately the recent Cardiosave recalls or did not receive the manufacturer’s customer letters, at 1-888-943-8872, Monday through Friday, between 8:00 a.m. and 6:00 p.m. EST.


The FDA recommendations from the November 2019 letter to health care providers have not changed for Maquet/Datascope IABP procedure users and servicers.


Background


The Maquet/Datascope lABP is a cardiac attend device placed in the descending aorta, just distal to the left subclavian artery. The device is an electromechanical system used to inflate and deflate intra-aortic balloons, which provides temporary support to the heart's left ventricle by increasing coronary perfusion and reducing left ventricular work. Getinge no longer manufactures the CS300 and CS100/CS100i IABP devices; nonetheless, these devices may still be in use. The today available Maquet/Datascope IABP devices are the Cardiosave Hybrid and Rescue.


Since 2017, the FDA has been evaluating medical procedure reports of Maquet/Datascope IABP devices shutting down. There may be multiple root shifts for the device failures, and the FDA continues to work with Getinge to understanding the root causes and possible risk mitigation measures. In 2019, the manufacturer initiated a voluntary remove due to the potential risk of battery failure in which Getinge contacted customers to schedule a arranging visit to review updated battery instructions, and instructions for use, care and maintenance. Additionally, the manufacturer provided a quick reference guide specific to each IABP procedure based on the Operating Instructions Manual(s).


At this time, the extent of the root repositions or incidence rate of Maquet/Datascope IABP devices shutting down while moving on battery power or AC power is not noted. The FDA continues to evaluate information from the manufacturer to resolve factors which may contribute to device failure events, as well as possible risk and mitigation measures.


The manufacturer is planning to implement software repositions for Cardiosave IABP devices that are intended to address emanates with batteries and device failures. The proposed software repositions need to be submitted to the FDA for reconsider and clearance. The manufacturer will install various internal and external component upgrades that will be made available in an Ingress Prevention Upgrade Kit for Cardiosave IABP devices. The manufacturer will also provide redesigned Display and Rescue Covers for Cardiosave Rescue IABP devices The FDA will work posthaste to review any changes from the manufacturer that may capture patient safety and will continue to monitor actions bodies taken by the manufacturer to address IABP device failure.


FDA Actions


The FDA stays to work with the manufacturer to examine and address the root repositions of Maquet/Datascope Cardiosave IABP device failures while running on battery much or AC power and will keep the public warned if any significant new information or recommendations become available.


Reporting Problems to the FDA


The FDA encourages health care providers to represent any adverse events or suspected adverse events experienced with Getinge Maquet/Datascope IABP devices.


Prompt reporting of adverse suits can help the FDA identify and better understand the risks associated with medical devices.


Contact Information


If you have questions near this letter, contact the Division of Industry and Consumer Education (DICE).




Thanks for visiting our article Getinge’s Maquet/Datascope IABP Devices: Update on Device Failure – Letter to Health Care Providers | FDA. Please share it with pleasure.

Source: www.fda.gov